Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
3 competitors in HIV Infections
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Kaletra
Kaletra is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children aged from 14 days and older. The choice of Kaletra to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.
View on EMAVaccines, Pneumococcal
Diabetes Mellitus
Renal Transplantation
Major Depressive Disorder
Complicated Intra-abdominal Infections